

Sandhoff Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/SBFDF40C267AEN.html>

Date: May 2024

Pages: 135

Price: US\$ 6,499.00 (Single User License)

ID: SBFDF40C267AEN

Abstracts

The 7 major Sandhoff disease markets are expected to exhibit a CAGR of 3.07% during 2024-2034.

The Sandhoff disease market has been comprehensively analyzed in IMARC's new report titled "Sandhoff Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sandhoff disease is a rare, inherited metabolic disorder that mainly affects the central nervous system. It is caused by the absence or insufficient activity of an enzyme called hexosaminidase A, which leads to the accumulation of certain fats (glycolipids) in the brain and nervous system. It usually occurs in infancy, but it can appear in children and adults too. The symptoms of this condition include abnormal bone development, awkward movements, cherry-red spots on the eyeballs, an enlarged head (macrocephaly) or enlarged liver and spleen, exaggerated reactions to loud noises, frequent respiratory infections, delayed development of motor skills, weak muscles, etc. In severe cases, infants suffering from Sandhoff disease may also experience hearing loss, paralysis, seizures, vision loss, and early death. The diagnosis of this ailment is typically made by a detailed evaluation of the patient's medical history, clinical manifestations, and physical examination. A blood workup to determine the level and activity of the hexosaminidase enzyme is also recommended. The healthcare professional may further perform genetic testing to identify gene mutations associated with the disease.

The increasing prevalence of lipid storage disorders on account of inherited deficiencies in producing functional catabolic enzymes is primarily driving the Sandhoff disease market. Apart from this, the widespread adoption of anticonvulsant drugs, including valproic acid and phenobarbital, to manage and control the symptoms of the ailment,

such as seizures, is also acting as another significant growth-inducing factor. Moreover, the escalating application of substrate reduction therapy using a glucosylceramide synthase inhibitor to decrease the buildup of glycolipids in cells, which further leads to the development of the disorder, is creating a positive outlook for the market. Additionally, several key players are making extensive investments in introducing novel disease-modifying therapeutic options that slowly target the progression of the illness while maintaining adequate nutrition and hydration. This, in turn, is also propelling the market growth. Furthermore, the emerging popularity of stem cell therapy for treating the ailment, since it helps in replacing the damaged cells in the brain and nervous system to restore the function of the affected areas, is expected to drive the Sandhoff disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Sandhoff disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Sandhoff disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Sandhoff disease market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Sandhoff disease market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Sandhoff disease market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Sandhoff disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the Sandhoff disease market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Sandhoff disease market across the seven major

markets in 2023 and what will it look like in 2034?

What is the growth rate of the Sandhoff disease market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Sandhoff disease across the seven major markets?

What is the number of prevalent cases (2018-2034) of Sandhoff disease by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Sandhoff disease by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Sandhoff disease across the seven major markets?

What is the size of the Sandhoff disease patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Sandhoff disease?

What will be the growth rate of patients across the seven major markets?

Sandhoff Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Sandhoff disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Sandhoff disease market?

What are the key regulatory events related to the Sandhoff disease market?

What is the structure of clinical trial landscape by status related to the Sandhoff disease market?

What is the structure of clinical trial landscape by phase related to the Sandhoff disease

market?

What is the structure of clinical trial landscape by route of administration related to the Sandhoff disease market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 SANDHOFF DISEASE - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 SANDHOFF DISEASE - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 SANDHOFF DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 SANDHOFF DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 SANDHOFF DISEASE - UNMET NEEDS

10 SANDHOFF DISEASE - KEY ENDPOINTS OF TREATMENT

11 SANDHOFF DISEASE - MARKETED PRODUCTS

- 11.1 List of Sandhoff Disease Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 SANDHOFF DISEASE - PIPELINE DRUGS

12.1 List of Sandhoff Disease Pipeline Drugs Across the Top 7 Markets

12.1.1 Drug Name – Company Name

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. SANDHOFF DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. SANDHOFF DISEASE – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 SANDHOFF DISEASE - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Sandhoff Disease - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Sandhoff Disease - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Sandhoff Disease - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Sandhoff Disease - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Sandhoff Disease - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Sandhoff Disease - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Sandhoff Disease - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Sandhoff Disease - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Sandhoff Disease - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Sandhoff Disease - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Sandhoff Disease - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Sandhoff Disease - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Sandhoff Disease - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Sandhoff Disease - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Sandhoff Disease - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Sandhoff Disease - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Sandhoff Disease - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Sandhoff Disease - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Sandhoff Disease - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Sandhoff Disease - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Sandhoff Disease - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Sandhoff Disease - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Sandhoff Disease - Access and Reimbursement Overview

16 SANDHOFF DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 SANDHOFF DISEASE MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 SANDHOFF DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Sandhoff Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/SBFDF40C267AEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SBFDF40C267AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

